文献速递神经肿瘤

2016年WHO分类更新后弥漫性高级别胶质瘤相关癫痫的特征、危险因素与临床结局

Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes.
PubMed 文献 · J Neurosurg · 2021-07-09

该回顾性研究纳入449例按2016年WHO分类确诊的弥漫性高级别胶质瘤患者,分析胶质瘤相关癫痫的流行病学特征、危险因素及预后价值。结果显示癫痫发生率随肿瘤恶性程度升高而降低,术前癫痫与年龄<45岁、神经功能正常及较低WHO分级独立相关,术后癫痫而非术前癫痫是总生存期的独立预后因素。

要点

  • 年龄<45岁、神经功能正常、较低WHO分级与术前胶质瘤相关癫痫独立相关。
  • 术前癫痫、颞叶受累、非全切除、较低WHO分级是术后癫痫控制不良的独立预测因素。
  • 术后胶质瘤相关癫痫而非术前癫痫是总生存期的独立预后因素。

核心结论

  • 2016年WHO分类有助于揭示弥漫性高级别胶质瘤患者中胶质瘤相关癫痫的分布。
  • 对具有癫痫控制不良高危预测因素的患者,及时抗癫痫干预可能有益。
  • 胶质瘤相关癫痫(尤其是术后癫痫)与较好的总生存期相关。

研究设计与样本

  • 回顾性收集449例弥漫性高级别胶质瘤患者数据,按2016年WHO分类重新确认诊断。
  • 术后12个月采用Engel分级评估癫痫结局,行单因素和多因素分析识别术前及术后癫痫危险因素。
  • 采用Kaplan-Meier和Cox分析评估胶质瘤相关癫痫的预后价值。

主要发现

  • 胶质瘤相关癫痫发生率随肿瘤恶性程度增加而逐渐降低。
  • 年龄<45岁(OR 2.601,p<0.001)、神经功能正常(OR 3.024,p<0.001)、较低WHO分级(OR 2.028,p=0.010)与术前癫痫独立相关。
  • 术前癫痫(OR 7.554,p<0.001)、颞叶受累(OR 1.954,p=0.033)、非全切除(OR 2.286,p=0.012)、较低WHO分级(OR 2.130,p=0.021)是术后癫痫控制不良的独立预测因素。
  • 术后胶质瘤相关癫痫而非术前癫痫是总生存期的独立预后因素(OR 0.610,p=0.010)。

临床怎么用

  • 对具有术前癫痫、颞叶受累、非全切除或较低WHO分级等高危因素的患者,应加强术后癫痫监测与及时干预。
  • 术后出现胶质瘤相关癫痫可能提示较好的总生存期,可作为预后评估的参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to investigate the epidemiological characteristics, associated risk factors, and prognostic value of glioma-related epilepsy in patients with diffuse high-grade gliomas (DHGGs) that were diagnosed after the 2016 updated WHO classification was released. METHODS: Data from 449 patients with DHGGs were retrospectively collected. Definitive diagnosis was reaffirmed according to the 2016 WHO classification. Seizure outcome was assessed using the Engel classification at 12 months after surgery. Univariate and multivariate analyses were performed to identify risk factors associated with preoperative and postoperative glioma-related epilepsy. Lastly, the prognostic value of glioma-related epilepsy was evaluated by Kaplan-Meier and Cox analysis. RESULTS: The incidence of glioma-related epilepsy decreased gradually as the malignancy of the tumor increased. Age < 45 years (OR 2.601, p < 0.001), normal neurological function (OR 3.024, p < 0.001), and lower WHO grade (OR 2.028, p = 0.010) were independently associated with preoperative glioma-related epilepsy, while preoperative glioma-related epilepsy (OR 7.554, p < 0.001), temporal lobe involvement (OR 1.954, p = 0.033), non-gross-total resection (OR 2.286, p = 0.012), and lower WHO grade (OR 2.130, p = 0.021) were identified as independent predictors of poor seizure outcome. Furthermore, postoperative glioma-related epilepsy, rather than preoperative glioma-related epilepsy, was demonstrated as an independent prognostic factor for overall survival (OR 0.610, p = 0.010). CONCLUSIONS: The updated WHO classification seems conducive to reveal the distribution of glioma-related epilepsy in DHGG patients. For DHGG patients with high-risk predictors of poor seizure control, timely antiepileptic interventions could be beneficial. Moreover, glioma-related epilepsy (especially postoperative glioma-related epilepsy) is associated with favorable overall survival.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Li L, Fang S, Li G, et al. Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes. J Neurosurg. 2021. PMID: 34243149. doi:10.3171/2020.12.JNS203351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。